Find an Article

Filter articles

Applied Filters

Showing 151 to 160 of 278 results

Biologic data exclusivity in Vietnam: change is on the horizon

Vietnam14-07-2016Hien Thi Thu Vu and Huong Lan Nguyen

Several legislative changes affecting data exclusivity of biologic drugs in Vietnam are poised to come into effect, and companies operating in this sector should take note now, as Hien Thi Thu Vu and Huong Lan Nguyen of Tilleke & Gibbins explain.

From the EU to Australia: latest SPC developments

Australia, EU07-07-2016Gareth Morgan

Legislative developments surrounding supplementary protection certificates in the EU are moving fast, and may be catching on as far afield as Australia. Gareth Morgan of Olswang explains more.

Brexit and IP: business as usual, for now

EU, UK07-07-2016Claire Phipps-Jones

Following the UK’s vote to leave the EU, it is business as usual for life sciences companies working with intellectual property, at least for now, says Claire Phipps-Jones of Bristows.

‘Brexit’: time is of the essence for life sciences innovators

EU30-06-2016Laetitia Benard

The UK’s vote to leave the EU has triggered an immediate need for innovative life sciences companies to evaluate the impact on their patent strategies, argues Laetitia Benard of Allen & Overy.

Putting the boot into biologic strategies

EU, UK30-06-2016Elizabeth Ward

Is it time for healthcare regulators and patent offices to limit the strategies used by existing biologic manufacturers and allow new suppliers to reach some of the world’s most lucrative healthcare systems? Elizabeth Ward of Virtuoso Legal investigates.

The value of secrecy for big pharma

EU23-06-2016Andy Sanderson and Ling Zhuang

While pharmaceutical companies are more likely to seek patent protection for their inventions, trade secrets can be useful too, particularly following two recent legislative developments, say Andy Sanderson and Ling Zhuang of Potter Clarkson.

An overview: revised biotech patent guidelines in Canada

Canada22-06-2016Jason Markwell and Stephanie Anderson

The Canadian Intellectual Property Office has updated its guidelines on procedural and examination practices, with some changes affecting biotechnology and medicinal inventions, explain Jason Markwell and Stephanie Anderson of Belmore Neidrauer.

Case report: Biocon’s breast cancer biosimilar gets green light

India16-06-2016Vikrant Rana and Sanjeeta Das

In a recent decision in India, biopharma company Biocon and its partner Mylan were allowed to continue marketing a biosimilar breast cancer drug, as Vikrant Rana and Sanjeeta Das of SS Rana report.

Optimising IP strategies: Life Sciences Law Forum preview


Ahead of the Life Sciences Law Forum 2016, which takes place on June 23 at Etc Venues in the City of London, LSIPR previews some of the main discussion points.

A proud history of innovation

Mexico10-06-2016Nuria Becerril

IP and innovation in Mexico has come a long way, and the country’s part in international trade treaties will provide further great opportunities, says Nuria Becerril of Becerril, Coca & Becerril.

Showing 151 to 160 of 278 results